Staphylococcus Aureus Bacteremia Among Patients with Health Care-associated Fever - 12/08/11
Abstract |
Background |
Although Staphylococcus aureus bacteremia is a common, serious infection, accurately identifying febrile patients with this diagnosis at the time of initial evaluation is difficult. The purpose of this investigation was to define clinical characteristics present at the time of the initial recognition of fever that were associated with the presence of any bloodstream infection and, in particular, with S. aureus bacteremia.
Methods |
All patients ≥18 years of age with a new episode of health care-associated fever (temperature ≥38°C) and at least one blood culture drawn were eligible for enrollment into this prospective multicenter cohort study. Multivariable analyses were conducted and internally validated scoring systems were developed to categorize the risk of bacteremia.
Results |
Of 1015 patients enrolled, 181 patients (17.8%) had clinically significant bacteremia, including 77 patients (7.6%) with S. aureus bacteremia. Clinical characteristics associated with S. aureus bacteremia were the presence of a hemodialysis graft or shunt (odds ratio [OR] 3.22; 95% confidence interval [CI], 1.85-5.61), chills (OR 2.38; 95% CI, 1.43-3.98), and a history of S. aureus infection (OR 2.68; 95% CI, 1.38-5.20). Peripheral vascular catheters were inversely associated with S. aureus bacteremia (OR 0.42; 95% CI, 0.26-0.69). Clinical characteristics associated with any bloodstream infection were central venous access, chills, history of S. aureus infection, and hemodialysis access.
Conclusions |
Among patients with health care-associated fever, the presence of easily recognizable clinical characteristics at the time of obtaining the initial blood cultures can help to identify patients at increased risk for any bloodstream infection, in particular for S. aureus bacteremia.
Le texte complet de cet article est disponible en PDF.Keywords : Bacteremia, Fever, Health care, S. aureus, Score
Plan
Funding: This work was supported by a grant from Inhibitex, Inc. Inhibitex did not intervene in: design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. |
|
Conflicts of Interest: Martin E. Stryjewski has consulted for Astellas (<$10,000), and has received a research grant (>$10,000) and is a consultant for Theravance Inc. (>$10,000/year). Vivian H. Chu has received a research grant from Theravance Inc. Vance G. Fowler has received research funding from Theravance, Merck, Nabi (<US$10,000/year), Inhibitex, Cubist, and the National Institute of Health; is a consultant for Biosynexus, Inhibitex, Merck, Cerexa, and Cubist; and is on the speaker's bureaus for Cubist and Pfizer. G. Ralph Corey has received research funding from Theravance, Cubist, Merck, and Inhibitex; and is a consultant for Cubist, Inhibitex, Cerexa, and Pfizer. Daniel K. Benjamin Jr. has received a research grant from Nabi, Cape Cod Associates, Astellas, MedImmune, Pediatrix, Rockeby, National Institute of Child Health and Human Development, and National Institute of Allergy and Infectious Diseases. Tina Harding, Laura A. Drew, Paul A. Pappas, Benjamin A. Lee, Zeina A. Kanafani, and L. Barth Reller have no conflicts. |
|
Authorship: All authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. |
Vol 122 - N° 3
P. 281 - mars 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?